Navigation Links
Microbia Announces Name Change to Ironwood Pharmaceuticals
Date:4/7/2008

CAMBRIDGE, Mass., April 7, 2008 /PRNewswire/ -- Microbia, Inc. today announced that it has changed its name to Ironwood Pharmaceuticals, Inc. The ironwood is a long-lived tree that thrives in the harshest desert environment, with some trees surviving as long as 1,500 years. Known as a "nurse tree," it provides a shaded microclimate with lower temperatures, higher water availability, and more organic matter for birds, reptiles, insects, animals, and plants. In addition, the name Ironwood encompasses the inorganic and organic -- the properties of essential elements and the characteristics of life.

"As Microbia has developed and progressed, we have outgrown the usefulness of the name Microbia," said Peter Hecht, CEO. "With that in mind, we sought a name for the company that reflects our approach to creating important human medicines. Because our research efforts are not limited to a single therapeutic area, we require a name that will accommodate a broad range of discoveries and products. We chose a name that not only suits us today, but also can endure for 100 years."

Additional information can be found at http://www.ironwoodpharma.com.

About Ironwood Pharmaceuticals (formerly Microbia)

Ironwood Pharmaceuticals (http://www.ironwoodpharma.com) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. The Company is advancing several clinical candidates -- linaclotide for the treatment of irritable bowel syndrome with constipation, chronic constipation and other functional gastrointestinal disorders; and novel, next-generation cholesterol absorption inhibitors for the treatment of hypercholesterolemia. Ironwood also has a growing pipeline of additional drug candidates in earlier stages of development. Microbia Precision Engineering, Inc., a majority-owned subsidiary of Ironwood Pharmaceuticals is an industrial biotechnology company developing and commercializing novel bioprocesses for the production of specialty chemicals. Ironwood has raised $231 million in private equity financing and is located in Cambridge, Massachusetts.

Contact:

Susan Brady

Corporate Communications

617|621-8304

sbrady@ironwoodpharma.com


'/>"/>
SOURCE Microbia, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. New Microbial Genome-to-Array Service
2. Change in Medicare and Medicaid Legislation Creates Market for Antimicrobial Coatings In the U.S.
3. Baxter Receives 510(k) Clearance From FDA For V-Link With VitalShield, New Antimicrobial Intravascular Technology
4. Innovative Fosshield(R) Antimicrobial Technology Shown to Continuously Kill MRSA Superbug
5. Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
6. SportCoatings; The North American Booster Club Association (NABCA); the Coatings Specialist Group New Booster Program Goes High Tech With Invisible Antimicrobial Defense
7. China YCT International Group, Inc. Announces Entrusted Management Agreement With Its Primary Supplier
8. Medicsight Announces New Marketing Partnership with INFINITT
9. Sangamo BioSciences Announces License Agreement For the Use of ZFP Technology For Generation of Transgenic Animals
10. Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
11. Angiotech announces commercial launch of Cook Medicals Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. (RCA), ... free webinar on Performing Quality Investigations: Getting to Root Cause. ... no charge. , Incomplete investigations are still a major concern to the Regulatory ...
Breaking Biology Technology:
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/1/2016)... June 1, 2016 Favorable Government ... Administration and Criminal Identification to Boost Global Biometrics System ... released TechSci Research report, " Global Biometrics Market ... Forecast and Opportunities, 2011 - 2021", the global biometrics ... 2021, on account of growing security concerns across various ...
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
Breaking Biology News(10 mins):